Alcobra Ltd. to Participate in Piper Jaffray 27th Annual Healthcare Conference

TEL AVIV, Israel, Nov. 24, 2015 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced participation in a panel titled "Underdiscovered NeuroInnovators" at the Piper Jaffray 27th Annual Healthcare Conference.

Piper Jaffray 27th Annual Healthcare Conference
Panel Title: "Underdiscovered NeuroInnovators"
Date: Wednesday, December 2
Time: 10:00am ET
Location: Lotte New York Palace, New York, NY
Presenter: Dr. Tomer Berkovitz, CFO

About Alcobra Ltd.

Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and FXS. For more information please visit the Company's website,, the content of which is not incorporated herein by reference.

CONTACT: U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 Media Inquiries Sam Brown, Inc. Mike Beyer 312-961-2502 Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661

Source:Alcobra Ltd.